Loading
A phase 3 trial of PM8002, Gemcitabine, Carboplatin and Eribulin in triple-negative breast cancer, run by BioNTech SE, now recruiting.
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer is a phase 3 interventional study registered as NCT07173751 by BioNTech SE, with 558 participants planned, started 2025-10-30 and due to reach its primary completion in 2029-12. Interventions recorded: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin and Matching placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eribulin, BioNTech, Bristol Myers Squibb, Gemcitabine and the tag pipeline.
Shares PM8002, BioNTech, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares PM8002, BioNTech, Bristol Myers Squibb and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/